HGH 176-191 is not full-length somatropin. It is a short synthetic fragment corresponding to residues 176-191 of human growth hormone, which means authenticity review should focus on peptide identity, HPLC purity, mass confirmation, lot traceability, and storage discipline rather than IGF-1 biomarker interpretation. For research buyers, this distinction matters: a fragment can share the hGH name while requiring a very different analytical review workflow.
What a Useful HGH 176-191 COA Should Show
HPLC purity: A batch-linked chromatogram should show the main peak and the purity percentage. Ourovia treats COA purity / HPLC purity as the core visible quality marker for this product class.
Mass confirmation: LC-MS or MS evidence should support the expected molecular identity for HGH 176-191. Public compound references commonly list CAS No. 66004-57-7 and formula C78H123N23O22S2 for this fragment, so analytical documents should be reviewed against the expected identity rather than generic hGH wording.
Lot matching: The lot number on the vial, product page, and analytical document should match. A polished PDF without a matching vial lot is weak evidence.
Why It Should Not Be Marketed Like Full-Length HGH
Full-length recombinant HGH is a 191-amino-acid protein with tertiary structure and protein-specific storage questions. HGH 176-191 is a short peptide fragment. The product language, parameter selection units, and analytical claims should therefore use mg-based peptide terminology rather than IU-based somatropin language.
Ourovia research note: Review HGH 176-191 as a research-use peptide fragment: confirm batch-linked HPLC purity, expected mass identity, storage conditions, and supplier transparency. Do not use full-length HGH claims, biomarker promises, or clinical language when evaluating this product.
